WO2002047672A3 - Treatment of cystic fibrosis with alkalinizing agents - Google Patents

Treatment of cystic fibrosis with alkalinizing agents Download PDF

Info

Publication number
WO2002047672A3
WO2002047672A3 PCT/US2001/047764 US0147764W WO0247672A3 WO 2002047672 A3 WO2002047672 A3 WO 2002047672A3 US 0147764 W US0147764 W US 0147764W WO 0247672 A3 WO0247672 A3 WO 0247672A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
treatment
alkalinizing agents
alkalinizing
agents
Prior art date
Application number
PCT/US2001/047764
Other languages
French (fr)
Other versions
WO2002047672A2 (en
Inventor
Vojo P Deretic
Jens F Poschet
J Cliff Boucher
Original Assignee
Univ Michigan
Vojo P Deretic
Jens F Poschet
J Cliff Boucher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Vojo P Deretic, Jens F Poschet, J Cliff Boucher filed Critical Univ Michigan
Priority to AU2002228970A priority Critical patent/AU2002228970A1/en
Publication of WO2002047672A2 publication Critical patent/WO2002047672A2/en
Publication of WO2002047672A3 publication Critical patent/WO2002047672A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods of treating cystic fibrosis, and in particular to exposing cystic fibrosis cells to alkalinizing agents.
PCT/US2001/047764 2000-12-11 2001-12-07 Treatment of cystic fibrosis with alkalinizing agents WO2002047672A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002228970A AU2002228970A1 (en) 2000-12-11 2001-12-07 Treatment of cystic fibrosis with alkalinizing agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25471200P 2000-12-11 2000-12-11
US60/254,712 2000-12-11

Publications (2)

Publication Number Publication Date
WO2002047672A2 WO2002047672A2 (en) 2002-06-20
WO2002047672A3 true WO2002047672A3 (en) 2003-05-15

Family

ID=22965287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047764 WO2002047672A2 (en) 2000-12-11 2001-12-07 Treatment of cystic fibrosis with alkalinizing agents

Country Status (2)

Country Link
AU (1) AU2002228970A1 (en)
WO (1) WO2002047672A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012470A1 (en) * 1994-10-20 1996-05-02 Alphagene, Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
WO1996034604A1 (en) * 1995-05-05 1996-11-07 Novartis Ag Inhibition of intracellular acidification
US5723496A (en) * 1991-03-05 1998-03-03 The Regents Of University Of California Method for prevention and treatment of harmful effects of intracellular acidosis
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723496A (en) * 1991-03-05 1998-03-03 The Regents Of University Of California Method for prevention and treatment of harmful effects of intracellular acidosis
WO1996012470A1 (en) * 1994-10-20 1996-05-02 Alphagene, Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
WO1996034604A1 (en) * 1995-05-05 1996-11-07 Novartis Ag Inhibition of intracellular acidification
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AXELSSON M A B ET AL: "Neutralization of pH in the Golgi apparatus causes redistribution of glycosyltransferases and changes in the O-glycosylation of mucins", GLYCOBIOLOGY, (AUG 2001) VOL. 11, NO. 8, PP. 633-644. PUBLISHER: OXFORD UNIV PRESS INC, JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA. ISSN: 0959-6658., Univ Gothenburg, Dept Biochem Med, POB 440, S-40530 Gothenburg, Sweden (Reprint);Univ Gothenburg, Dept Biochem Med, S-40530 Gothenburg, Sweden; EMBL, Cell Biol & Biophys Programme, D-69017 Heidelberg,, XP008005946 *
POSCHET J F ET AL: "Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 24, 20 November 2001 (2001-11-20), November 20, 2001, pages 13972 - 13977, XP001089858, ISSN: 0027-8424 *
POSCHET JENS F ET AL: "Hyperacidification of cellubrevin endocytic compartments and defective endosomal recycling in cystic fibrosis respiratory epithelial cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 16, 19 April 2002 (2002-04-19), April 19, 2002, pages 13959 - 13965, XP001089863, ISSN: 0021-9258 *
POSCHET JENS F ET AL: "Trans-Golgi network and cellubrevin endosomal compartments are hyperacidified in cystic fibrosis lung epithelial cells.", MOLECULAR BIOLOGY OF THE CELL, vol. 11, no. Supplement, December 2000 (2000-12-01), 40th American Society for Cell Biology Annual Meeting;San Francisco, CA, USA; December 09-13, 2000, pages 134a, XP008005913, ISSN: 1059-1524 *

Also Published As

Publication number Publication date
AU2002228970A1 (en) 2002-06-24
WO2002047672A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
NO20013554L (en) Anticonvulsant derivatives that can be used in the treatment of cluster headaches
MXPA03005893A (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs.
ID28981A (en) HEKSANA 3-AZABISIKLO (3.1.0) USES IN THERAPY
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
AU2001237996A1 (en) Thermally and chemically treating cells
AU2002211379A1 (en) Compositions and methods for treatment of cystic fibrosis
IS5504A (en) Composition active in the treatment of impotence
HK1045302A1 (en) Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders.
NO20013493L (en) Use of neurotrophin and its analogues in the treatment of gastrointestinal hypomotility disorders
IL161667A0 (en) Method and composition to treat cystic fibrosis
AU3262797A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
NO20033434D0 (en) 3,7-diazabicyclo (3.3.0) octanes and their use in the treatment of cardiac arrhythmias
AU2002227247A1 (en) Biofilm therapy process and elements
WO2002047672A3 (en) Treatment of cystic fibrosis with alkalinizing agents
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
WO2003032899A3 (en) Methods and materials for targeting and affecting selected cells
AU9352401A (en) Production process and composition of an enzymatic preparation, and its use for the treatment of domestic and industrial effluents of high fat, protein and/or carbohydrate content
AU2001275959A1 (en) Method of treating the syndrome of type 2 diabetes in humans
AU2001261360A1 (en) R-eliprodil for treating glaucoma
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
HK1056828A1 (en) Treatment of burns.
GB0108831D0 (en) Use of 1,10 and 1,7 and 4,7 phenanthroline, and of 7,8 benzoquinline and of phenanthridine and their derivatives in the treatment of cystic fibrosis and other
WO1999024052A3 (en) Use of protein h as cytostatic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP